Vaccines

OCU500: Bivalent COVID-19 inhaled vaccine
OCU510: Seasonal quadrivalent flu inhaled vaccine
OCU520: Combination quadrivalent seasonal flu and bivalent COVID-19 inhaled vaccine.

The OCU500 vaccine series is based on a novel ChAd platform designed to reduce transmission and protect against new variants with long-term durability.

Inhalation technology as a differentiator

• Multiple preclinical studies using Ocugen’s vector demonstrated vaccine-induced high neutralizing and effector responses
• Clinical studies using a similar vector administered via the inhalation platform showed mucosal antibodies, systemic antibodies, and durable immune response up to 1 year with 1/5 of the dose compared to the same vaccine given via intramuscular administration
• The inhaled method offers the potential for broad, durable protection from severe disease and reduction in transmission

Other features include:

• Non-invasive
• Needle-free administration
• Potential for increased compliance
• Scalable manufacturing
• Stored and shipped at standard refrigerated conditions
• Potential to develop multi-strain and variant specific versions